MedTrace Logo

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

NCT07034690 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.

Conditions

Interventions

OTHER

Educational Material

Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)

OTHER

Standard of care

Standard of care

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-26
Primary Completion
2027-05-31
Completion
2028-05-31

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07034690 on ClinicalTrials.gov